Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Incyte Corp (NASDAQ: INCY) closed at $62.01 down -8.62% from its previous closing price of $67.86. In other words, the price has decreased by -$8.62 from its previous closing price. On the day, 5.18 million shares were traded. INCY stock price reached its highest trading level at $63.45 during the session, while it also had its lowest trading level at $58.95.
Ratios:
For a deeper understanding of Incyte Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.56 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 48.18. For the most recent quarter (mrq), Quick Ratio is recorded 1.94 and its Current Ratio is at 1.97. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on December 17, 2024, initiated with a Neutral rating and assigned the stock a target price of $77.
On October 29, 2024, BofA Securities Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $68 to $90.
On October 01, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $84.Wolfe Research initiated its Outperform rating on October 01, 2024, with a $84 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 14 ’25 when BARRY FLANNELLY bought 19,807 shares for $67.69 per share.
Denton Sheila A. sold 599 shares of INCY for $41,924 on Mar 04 ’25. The EVP & General Counsel now owns 25,848 shares after completing the transaction at $69.99 per share. On Mar 04 ’25, another insider, SHEILA DENTON, who serves as the Officer of the company, bought 599 shares for $69.99 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INCY now has a Market Capitalization of 12000422912 and an Enterprise Value of 9902690304. As of this moment, Incyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 228.65, and their Forward P/E ratio for the next fiscal year is 9.45. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.38. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.83 while its Price-to-Book (P/B) ratio in mrq is 3.48. Its current Enterprise Value per Revenue stands at 2.335 whereas that against EBITDA is 55.759.
Stock Price History:
The Beta on a monthly basis for INCY is 0.85, which has changed by 0.06308937 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, INCY has reached a high of $83.95, while it has fallen to a 52-week low of $50.35. The 50-Day Moving Average of the stock is -13.23%, while the 200-Day Moving Average is calculated to be -8.44%.
Shares Statistics:
For the past three months, INCY has traded an average of 1.67M shares per day and 1884670 over the past ten days. A total of 193.43M shares are outstanding, with a floating share count of 190.72M. Insiders hold about 1.45% of the company’s shares, while institutions hold 95.46% stake in the company. Shares short for INCY as of 1740700800 were 5846755 with a Short Ratio of 3.51, compared to 1738281600 on 5788151. Therefore, it implies a Short% of Shares Outstanding of 5846755 and a Short% of Float of 5.35.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Incyte Corp (INCY) is currently in the spotlight, with 12.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $1.46, with high estimates of $1.68 and low estimates of $1.3.
Analysts are recommending an EPS of between $7.23 and $4.84 for the fiscal current year, implying an average EPS of $5.89. EPS for the following year is $6.6, with 15.0 analysts recommending between $9.49 and $2.09.
Revenue Estimates
A total of 17 analysts believe the company’s revenue will be $999.85M this quarter.It ranges from a high estimate of $1.1B to a low estimate of $918.51M. As of the current estimate, Incyte Corp’s year-ago sales were $880.89MFor the next quarter, 17 analysts are estimating revenue of $1.15B. There is a high estimate of $1.21B for the next quarter, whereas the lowest estimate is $1.1B.
A total of 22 analysts have provided revenue estimates for INCY’s current fiscal year. The highest revenue estimate was $4.81B, while the lowest revenue estimate was $4.57B, resulting in an average revenue estimate of $4.67B. In the same quarter a year ago, actual revenue was $4.24BBased on 21 analysts’ estimates, the company’s revenue will be $5.12B in the next fiscal year. The high estimate is $5.51B and the low estimate is $4.75B.
